473 related articles for article (PubMed ID: 8765516)
1. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor.
Beyermann M; Fechner K; Furkert J; Krause E; Bienert M
J Med Chem; 1996 Aug; 39(17):3324-30. PubMed ID: 8765516
[TBL] [Abstract][Full Text] [Related]
2. Minimal-size, constrained corticotropin-releasing factor agonists with i-(i+3) Glu-Lys and Lys-Glu bridges.
Rivier J; Lahrichi SL; Gulyas J; Erchegyi J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W
J Med Chem; 1998 Jul; 41(14):2614-20. PubMed ID: 9651165
[TBL] [Abstract][Full Text] [Related]
3. Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c[Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors.
Haskell-Luevano C; Nikiforovich G; Sharma SD; Yang YK; Dickinson C; Hruby VJ; Gantz I
J Med Chem; 1997 May; 40(11):1738-48. PubMed ID: 9171884
[TBL] [Abstract][Full Text] [Related]
4. Effects of side-chain characteristics on stability and oligomerization state of a de novo-designed model coiled-coil: 20 amino acid substitutions in position "d".
Tripet B; Wagschal K; Lavigne P; Mant CT; Hodges RS
J Mol Biol; 2000 Jul; 300(2):377-402. PubMed ID: 10873472
[TBL] [Abstract][Full Text] [Related]
5. Novel anti-inflammatory undecapeptides that contain anisolyated glutamic acid derivatives.
Thomas HA; Ling N; Wei ET; Berree F; Cobas A; Rapoport H
J Pharmacol Exp Ther; 1993 Dec; 267(3):1321-6. PubMed ID: 7903386
[TBL] [Abstract][Full Text] [Related]
6. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
7. Functional evidence for an intramolecular side chain interaction between residues 6 and 10 of receptor-bound parathyroid hormone analogues.
Shimizu N; Petroni BD; Khatri A; Gardella TJ
Biochemistry; 2003 Mar; 42(8):2282-90. PubMed ID: 12600195
[TBL] [Abstract][Full Text] [Related]
8. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
[TBL] [Abstract][Full Text] [Related]
9. Alanine series of ovine corticotropin releasing factor (oCRF): a structure-activity relationship study.
Kornreich WD; Galyean R; Hernandez JF; Craig AG; Donaldson CJ; Yamamoto G; Rivier C; Vale W; Rivier J
J Med Chem; 1992 May; 35(10):1870-6. PubMed ID: 1316969
[TBL] [Abstract][Full Text] [Related]
10. Corticotropin releasing factor (CRF) agonists with reduced amide bonds and Ser7 substitutions.
Cervini L; Theobald P; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1999 Feb; 42(4):761-8. PubMed ID: 10052982
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist.
Bennett MA; Murray TF; Aldrich JV
J Pept Res; 2005 Mar; 65(3):322-32. PubMed ID: 15787962
[TBL] [Abstract][Full Text] [Related]
12. Development of potent thrombin receptor antagonist peptides.
Bernatowicz MS; Klimas CE; Hartl KS; Peluso M; Allegretto NJ; Seiler SM
J Med Chem; 1996 Dec; 39(25):4879-87. PubMed ID: 8960546
[TBL] [Abstract][Full Text] [Related]
13. Constrained corticotropin-releasing factor (CRF) agonists and antagonists with i-(i+3) Glu-Xaa-DXbb-Lys bridges.
Koerber SC; Gulyas J; Lahrichi SL; Corrigan A; Craig AG; Rivier C; Vale W; Rivier J
J Med Chem; 1998 Dec; 41(25):5002-11. PubMed ID: 9836618
[TBL] [Abstract][Full Text] [Related]
14. Purification and structural characterization of insulin and glucagon from the bichir Polypterus senegalis (Actinopterygii: Polypteriformes).
Conlon JM; Fan H; Fritzsch B
Gen Comp Endocrinol; 1998 Jan; 109(1):86-93. PubMed ID: 9446726
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective agonists of alpha-melanotropin (alphaMSH) action at human melanocortin receptor 5; linear analogs of alpha-melanotropin.
Bednarek MA; MacNeil T; Tang R; Fong TM; Cabello MA; Maroto M; Teran A
Peptides; 2007 May; 28(5):1020-8. PubMed ID: 17376561
[TBL] [Abstract][Full Text] [Related]
16. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
Rivier J; Gulyas J; Corrigan A; Martinez V; Craig AG; Taché Y; Vale W; Rivier C
J Med Chem; 1998 Dec; 41(25):5012-9. PubMed ID: 9836619
[TBL] [Abstract][Full Text] [Related]
17. Constrained corticotropin-releasing factor antagonists with i-(i + 3) Glu-Lys bridges.
Miranda A; Lahrichi SL; Gulyas J; Koerber SC; Craig AG; Corrigan A; Rivier C; Vale W; Rivier J
J Med Chem; 1997 Oct; 40(22):3651-8. PubMed ID: 9357532
[TBL] [Abstract][Full Text] [Related]
18. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat.
Rivier JE; Kirby DA; Lahrichi SL; Corrigan A; Vale WW; Rivier CL
J Med Chem; 1999 Aug; 42(16):3175-82. PubMed ID: 10447963
[TBL] [Abstract][Full Text] [Related]
19. Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels.
Gardner A; Westfall TC; Macarthur H
J Pharmacol Exp Ther; 2005 Jun; 313(3):1109-17. PubMed ID: 15687374
[TBL] [Abstract][Full Text] [Related]
20. An investigation of position 3 in arginine vasopressin with aliphatic, aromatic, conformationally-restricted, polar and charged amino acids.
Stoev S; Cheng LL; Olma A; Klis WA; Manning M; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1999 Mar; 5(3):141-53. PubMed ID: 10323558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
